Sen­ate user fee reau­tho­riza­tion bill omits ac­cel­er­at­ed ap­proval re­forms, shows wide gaps with House ver­sion

1 hour ago
Pharma
FDA+

As new C. diff treat­ments prep for mar­ket, spe­cial­ists di­vid­ed on 'poop in a pil­l' or small mol­e­cule, study finds

1 hour ago
Pharma
Marketing

MRx roundup: Ho­log­ic en­lists Sh­eryl Crow for screen­ings; J&J Quick­Fire teams with feds for pub­lic health

3 hours ago
Pharma
Marketing

Per­pet­u­al cri­sis? Phar­ma com­mu­ni­ca­tions and pub­lic re­la­tions pros just wait for the next shoe to drop

3 hours ago
Pharma
Marketing

A long time com­ing: Glax­o­SmithK­line of­fi­cial­ly changes name to GSK

3 hours ago
R&D

Ge­nomics biotech un­der­goes a facelift, re­brand­ing from Clover to Char­ac­ter Bio­sciences

5 hours ago
Deals
R&D

Amidst R&D reshuf­fle, Ver­tex ex­pands its pres­ence in Boston, aim­ing to be­come num­ber one

6 hours ago
R&D
Manufacturing

Bear mar­ket forces Schol­ar Rock, po­ten­tial­ly years away from piv­otal SMA da­ta, to lay off a fourth of its staff

9 hours ago
People
R&D

A CRL lat­er, Gilead clears clin­i­cal hold on next-gen HIV drug — af­ter find­ing a new glass vial for it

9 hours ago
FDA+

An­oth­er pri­vate eq­ui­ty gi­ant makes a big move in­to biotech as Apol­lo ex­e­cutes €1B play — while life sci stocks shriv­el

Yesterday
R&D

Stay­ing in the back seat to Keytru­da, Bris­tol My­ers re­ports an­oth­er piv­otal set­back in urothe­lial can­cer

Yesterday
R&D
Pharma

Seek­ing a come-from-be­hind win, Eli Lil­ly lands big ap­proval for next-gen di­a­betes drug

Yesterday
Pharma
FDA+

UP­DAT­ED: Clay Sie­gall re­signs from Seagen amid in­ves­ti­ga­tion in­to do­mes­tic vi­o­lence claims

Yesterday
People

Pfiz­er's $11.6B wa­ger; TIG­IT im­plo­sion; An un­usu­al phar­ma-biotech pact; In­side a16z's vi­sion to re­shape biotech; and more

3 days ago
Weekly

Roche chair­man Christoph Franz of­fers glint of hope af­ter tiragolum­ab fail — re­port

4 days ago
Pharma

Strik­ing mu­rals in US cities high­light Hori­zon and Arthri­tis Foun­da­tion col­lab for gout aware­ness

4 days ago
Pharma
Marketing

UK gener­ics mak­er shut­ters, elim­i­nat­ing 1,000 jobs

4 days ago
Pharma
Manufacturing

Roche ends a bad, no good, plain lousy week with a $0 co-pay copy­cat stalk­ing one of its block­busters

4 days ago
Pharma

Roche's TIG­IT fall­out caus­es GSK and iTeos to re-think their own I/O can­di­date

4 days ago
R&D
Pharma

Re­gen­eron did­n't want to 'bid against it­self' in Check­mate deal as five glob­al phar­mas de­clined to coun­terof­fer

4 days ago
Deals
Pharma

Quash­ing block­buster hopes, FDA spurns UCB’s IL-17 drug for plaque pso­ri­a­sis

4 days ago
R&D
FDA+

Work­ing to right the ship, Bridge­Bio's Neil Ku­mar adds a $110M deal right on top of his cash haul from Bris­tol My­ers

4 days ago
Deals
Bioregnum

CSL's $11.7B buy­out hits an­titrust de­lay — is it a sign of what's to come?

5 days ago
Pharma

Boy bands and pso­ri­at­ic arthri­tis? NSYNC’s Lance Bass cre­ates new dance for Am­gen about ear­ly signs

5 days ago
Pharma
Marketing
1234 Next page Last page